Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430920 | 0.97 | LMNA (0.49) | LMNASMN1; SMN2PKML3MBTL1POLB | |
| SCHEMBL3231499 | 0.95 | LMNA (0.50) | LMNASMN1; SMN2PKML3MBTL1POLB | |
| SCHEMBL4422355 | 0.87 | LMNA (0.51) | LMNASMN1; SMN2PKML3MBTL1POLB | |
| SCHEMBL9557298 | 0.85 | TSHR (0.45) | L3MBTL1HPGDTSHRELANE | |
| SCHEMBL9557480 | 0.82 | THRA (0.43) | TSHR | |
| SCHEMBL3230845 | 0.81 | LMNA (0.46) | LMNASMN1; SMN2PKML3MBTL1POLB | |
| SCHEMBL5485257 | 0.81 | KDM4E (0.41) | TSHRELANE | |
| SCHEMBL4426186 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2PKM | |
| SCHEMBL14216107 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2PKML3MBTL1POLB | |
| SCHEMBL20067122 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2PKML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | claimed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | claimed |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9757399-B2 | Butyrylcholinesterase inhibitors | JAL THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757399-B2 | Butyrylcholinesterase inhibitors | JAL THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| EP-2097428-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Mgp Biotechnologies, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055249-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055249-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | BCHE, ACHE, PSEN1 | LMNA 1641/4885SMN1; SMN2 178/4885PKM 746/4885 |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | BCHE, ACHE, PSEN1 | LMNA 1641/4885SMN1; SMN2 178/4885PKM 746/4885 |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | BCHE, ACHE, PSEN1 | LMNA 1641/4885SMN1; SMN2 178/4885PKM 746/4885 |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | LMNA 2268/4885SMN1; SMN2 415/4885PKM 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.